What is the price target for TEVA stock?
7 analysts have analysed TEVA and the average price target is 0.11 USD. This implies a price decrease of -99.63% is expected in the next year compared to the current price of 29.82.
TEVA PHARMACEUTICAL-SP ADR (TEVA) Forecast, Price Target & Analyst Ratings
NYSE:TEVA • US8816242098
Current stock price
29.82 USD
-0.26 (-0.86%)
At close:
29.83 USD
+0.01 (+0.03%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TEVA PHARMACEUTICAL-SP ADR (TEVA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Apr 29, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.53
- Revenue Estimate
- 3.877B
Price Target Details & History
Consensus Price Target and Range
Mean target
$0.11
Upside
-99.63%
From current price of $29.82 to mean target of $0.11, Based on 7 analyst forecasts
Low
$0.11
Median
$0.11
High
$0.11
Price Target Revisions
1 Month
0.00%
3 Months
2.76%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for TEVA. The average price target is 0.11 USD. This implies a price decrease of -99.63% is expected in the next year compared to the current price of 29.82.
The average price target has been revised upward by 2.76% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
TEVA was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about TEVA.
In the previous month the buy percentage consensus was at a similar level.
TEVA was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-04 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2026-02-18 | Truist Securities | Maintains | Buy -> Buy |
| 2026-02-09 | Goldman Sachs | Maintains | Buy -> Buy |
| 2026-01-30 | Barclays | Maintains | Overweight -> Overweight |
| 2026-01-29 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2026-01-29 | Truist Securities | Maintains | Buy -> Buy |
| 2026-01-06 | Jefferies | Maintains | Buy -> Buy |
| 2025-12-22 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-12-19 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-12-16 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-12-09 | Barclays | Initiate | Overweight |
| 2025-12-09 | B of A Securities | Maintains | Buy -> Buy |
| 2025-12-08 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-12-05 | ScotiaBank | Initiate | Sector Outperform |
| 2025-11-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-03 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-24 | UBS | Maintains | Buy -> Buy |
| 2025-06-26 | UBS | Maintains | Buy -> Buy |
| 2025-06-06 | Goldman Sachs | Initiate | Buy |
| 2025-05-28 | Truist Securities | Initiate | Buy |
| 2025-05-12 | JP Morgan | Upgrade | Neutral -> Overweight |
| 2025-05-08 | B of A Securities | Maintains | Buy -> Buy |
| 2025-03-06 | B of A Securities | Maintains | Buy -> Buy |
| 2025-01-30 | UBS | Maintains | Buy -> Buy |
| 2025-01-30 | Barclays | Maintains | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Apr 29, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.53
- Revenue Estimate
- 3.877B
- Revenue Q2Q
- -0.36%
- EPS Q2Q
- 1.80%
- Number of Analysts
- 6
Next Earnings Revisions
Revenue (1 Month)
0.03%
Revenue (3 Months)
-4.20%
EPS (1 Month)
2.03%
EPS (3 Months)
-6.41%
Next Earnings Summary
TEVA is expected to report earnings on 4/29/2026. The consensus EPS estimate for the next earnings is 0.53 USD and the consensus revenue estimate is 3.88B USD.
The next earnings revenue estimate has been revised downward by 4.2% in the past 3 months.
Full Analyst Estimates 2026 - 2028
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 15.846B 6.17% | 16.544B 4.40% | 17.258B 4.32% | 16.922B -1.95% | 17.47B 3.24% | 18.191B 4.13% | |
| EBITDA YoY % growth | 4.693B 4.45% | 4.647B -0.98% | 5.14B 10.61% | 5.166B 0.51% | 5.543B 7.30% | 6.161B 11.15% | |
| EBIT YoY % growth | 3.54B 11.15% | 3.588B 1.36% | 4.138B 15.33% | 4.747B 14.72% | 5.234B 10.26% | 5.626B 7.49% | |
| Operating Margin | 22.34% | 21.69% | 23.98% | 28.05% | 29.96% | 30.93% | |
| EPS YoY % growth | 2.58 1.19% | 2.51 -2.73% | 2.94 17.27% | 2.78 -5.45% | 3.12 12.19% | 3.50 12.29% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.53 1.80% | 0.67 1.54% | 0.76 -3.14% | 0.77 -19.82% | 0.72 34.87% | 0.78 15.68% | 0.84 10.71% | 0.89 15.28% |
| Revenue Q2Q % growth | 3.877B -0.36% | 4.21B 0.81% | 4.414B -1.47% | 4.399B -6.62% | 4.19B 8.07% | 4.385B 4.16% | 4.532B 2.67% | 4.558B 3.61% |
| EBITDA Q2Q % growth | 1.033B 0.39% | 1.292B -10.40% | 1.427B -23.36% | 1.463B -36.58% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 1.006B 28.15% | 1.149B 21.20% | 1.272B 13.57% | 1.321B 1.23% | 1.191B 18.39% | 1.275B 10.97% | 1.359B 6.84% | 1.411B 6.81% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
6.00%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
1.74%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
11.69%
EBIT Next 5 Year
N/A
TEVA PHARMACEUTICAL-SP ADR / TEVA Forecast FAQ
When does TEVA PHARMACEUTICAL-SP ADR (TEVA) report earnings?
TEVA PHARMACEUTICAL-SP ADR (TEVA) will report earnings on 2026-04-29.
What are the consensus estimates for TEVA stock next earnings?
The consensus EPS estimate for the next earnings of TEVA PHARMACEUTICAL-SP ADR (TEVA) is 0.53 USD and the consensus revenue estimate is 3.88B USD.
How many analysts cover TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?
The number of analysts covering TEVA PHARMACEUTICAL-SP ADR (TEVA) is 7.